Side-by-side comparison of AI visibility scores, market position, and capabilities
Tucuvi's LOLA is the first EU Class IIb certified AI medical voice agent; in 60+ health systems with $20M Series A, running post-discharge follow-ups and chronic care check-ins (Jan 2026).
Tucuvi is a Spanish clinical AI company that has developed LOLA, a conversational voice AI agent for healthcare. LOLA conducts automated clinical conversations with patients — including post-discharge follow-ups, chronic disease monitoring check-ins, pre-appointment screenings, and medication adherence calls — with the tone, clinical accuracy, and empathy expected of a skilled nurse or care coordinator. Tucuvi was founded by a team combining clinical expertise and AI engineering to address the growing gap between care demand and available clinical staff in European health systems.\n\nThe LOLA platform integrates with hospital information systems and electronic health records, enabling health systems to deploy automated voice interactions at scale across their patient populations. The system is multilingual and capable of conducting clinically meaningful conversations that capture structured data, flag deteriorating patients, and escalate to human clinicians when needed. Unlike general-purpose voice assistants, LOLA is specifically trained on clinical language, patient interaction patterns, and healthcare workflows.\n\nTucuvi achieved a landmark regulatory milestone by becoming the first EU Class IIb certified AI medical device in the voice AI category, a certification level that covers devices posing moderate to high risk — the same classification as many implantable devices. This certification is a significant commercial differentiator in Europe's tightly regulated healthcare market. The company raised a $20M Series A, serves 60+ health systems, and has conducted 300,000+ clinical voice calls. Its 2025–2026 momentum reflects growing European health system interest in AI that can extend care capacity without adding nursing headcount.
$500M Series D at $11B valuation (Feb 2026) — largest voice AI funding round ever. $330M ARR; 1M+ developers using the API. Enterprise customers: Deutsche Telekom, Revolut, Meta, Salesforce. Voices in 32 languages; real-time cloning from 1 second of audio.
ElevenLabs was founded in 2022 by Piotr Dabkowski and Mati Staniszewski, two former Google and Palantir engineers who set out to break the language barrier using AI voice technology. The company specializes in AI-powered voice synthesis, cloning, and dubbing, enabling developers and enterprises to generate human-quality speech in over 30 languages. Its core technology combines deep learning models trained on massive speech datasets to produce natural-sounding voices indistinguishable from real humans.\n\nElevenLabs offers a suite of products including its flagship text-to-speech API, voice cloning tools, and an AI dubbing platform that localizes video content while preserving the speaker's original voice. Its products target a broad audience—from indie developers building audio apps to large enterprises deploying voice interfaces at scale. Key differentiators include ultra-low latency streaming synthesis, fine-grained voice customization, and a growing library of pre-built AI voices across accents and styles.\n\nElevenLabs has grown rapidly, surpassing $330M in annualized revenue and serving over 1 million developers. Enterprise clients include Deutsche Telekom, Spotify, and leading media companies. In February 2026, the company closed a $500M Series D at an $11B valuation, cementing its position as the market leader in AI voice. Its APIs power podcasts, audiobooks, video games, and customer service bots worldwide, making ElevenLabs the default infrastructure layer for AI-generated audio.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.